Luglio/Agosto - Sigot.Org

BIBLIOGRAFIA
1. CLEUSA P., FERRI, MARTIN PRINCE, et al.: for
Alzheimer’s Disease International. Global prevalence
of dementia: a Delphi consensus study.
Lancet 2005; 366: 2112-2117.
2. LOBO A., LAUNER L.J., FRATIGLIONI L., et al.:
for the Neurologic Disease in the Elderly Research
Group. Prevalence of dementia and major subtypes
in Europe: a collaborative study of populationbased
cohorts. Neurology 2000; 54 (suppl 5): S4-S9.
3. HARDY J., SELKOE D.J.: The amyloid hypothesis
of Alzheimer’s disease: progress and problems on
the road to therapeutics. Science 2002; 297: 353-356.
4. SILVERMAN D.H., SMALL G.W., CHANG C.Y.,
et al.: Positron emission tomography in evaluation
of dementia: regional brain metabolism and longterm
outcome. JAMA 2001; 286: 2120-2127.
5. CARTER D.B., DUNN E., MCKINLEY D.D., et
al.: Human apolipoprotein E4 accellerates betaamyloid
deposition in APPsw transgenic mouse
brain. Ann Neurol 2001; 50: 468-475.
6. PAPPAS B.A., BAYLEY P.J., BUI B.K., HANSEN
L.A., THAL L.J.: Choline acetyltransferase activity
and cognitive domain scores of Alzheimer’s
patients. Neurobiol Aging 2000; 21: 11-17.
7. HOCK C., KONIETZKO U., STREFFER J.R., et
al.: Antibodies against beta-amyloid slow cognitive
decline in Alzheimer’s disease. Neuron 2003; 38:
547-554.
8. CUMMINGS J.L.: Use of cholinesterase inhibitors
in clinical practice: evidence based recommendations.
Am J Geriatr Psychiatry 2003; 11: 131-145.
9. LEBER P.: Guidelines for the clinical evaluation
of antidementia drugs. Rockville, MD.: Food and
Drugs Administration, 1990.
10. Watkins PB, Zimmerman HJ, Knapp MJ, et al.
Hepatotoxic effects of tacrine administration in
patients with Alzheimer disease. JAMA 1994; 271:
992.
11. OTT B.R., OWENS N.J.: Complementary and
alternative medicines for Alzheimer’s disease. J
Geriatr Psychiatry Neurol 1998; 11: 163-173.
12. FELDMAN H., et al.: Donepezil MSAD study
investigators group. Efficacy and safety of donepezil
in patients with more severe Alzheimer’s disease:
a subgroup analysis from a randomized, placebo-controlled
trial. Int J Geriatr Psychiatry 2005; 20:
559-569.
13. WINBLAD B., KILANDER L., et al.: for the
Severe Alzheimer’s Disease Study Group.
Donepezil in patients with severe Alzheimer’s
Disease: double-blind, parallel-group, placebo-controlled
study. Lancet 2006; 367: 1057-1065.
14. WILKINSON D.G., MURRAY J., in collaboration
with the Galantamine Research Group.
(2001a). Galantamine: A randomised double-blind,
dose-comparison in patients with Alzheimer’s
disease. International Journal of Geriatric
Psychiatry, 16, 852-857.
15. RÖSLER M., ANAND R., CICIN-SAIN A.,
GAUTHIER S., AGID Y., et al.: (1999a). Efficacy and
safety of rivastigmine in patients with Alzheimer’s
disease: An international randomised controlled
trial. British Medical Journal, 318, 633-640.
16. DANYSZ W., PARSONS A.C.: Glycine and Nmethyl-D-aspartate
receptor: physiological signifi-
Geriatria
cance and possible therapeutic applications.
Pharmacol Rev 1998; 50: 597.
17. LANCELOT E., BEAL M.F.: Glutamate toxicity
in chronic neurodegenerative disease. Prog Brain
Res 1998; 116: 331.
18. REISBERG B., DOODY R., STOFFLER A. et al.:
A 24-week open-label extension study of
Memantine in moderate to severe Alzheimer disease.
Arch Neurol 2006; 63: 49-54.
19. TARIOT P.N., FARLOW M.R., GROSSBERG
G.T. et al.: Memantine treatment in patients with
moderate to severe Alzheimer’s disease already
receiving donepezil: A randomised controlled trial.
JAMA 2004; 291-317.
20. DANTOINE T., AURIACOMBE S., et al.:
Rivastigmine monotherapy and combination therapy
with memantine in patients with moderately
severe Alzheimer’s disease who failed to benefit
from previous cholinesterase inhibitor treatment.
Int J Clin Pract 2006; 60: 110-118.
21. VIÑA J., LLORET A., ORTI R., ALONSO D.:
Molecular bases of the treatment of Alzheimer’s disease
with antioxidants: prevention of oxidative stress.
Molecular Aspects of Medicine 2004; 25: 117-123.
22. GRUNDMAN M., DELANEY P.: Antioxidant
strategies for Alzheimer’s disease. Proc Nutr Soc
2005; 61, 2, 191-202.
23. ZANDI P.P., ANTHONY J.C.,
KHACHATURIAN A.S. et al.: Reduced risk of
Alzheimer’s disease in users of antioxidant vitamin
supplements: the Cache County Study. Arch
Neurol Jan 2004; 61: 82-88.
24. SANO M., ERNESTO C., THOMAS R.G. et al.:
A controlled trial of selegiline, alpha-tocopherol, or
both as treatment for Alzheimer’s disease. N Engl J
Med 1997; 336: 1216-1222.
25. MORRIS M.C., EVANS D.A., TANGNEY C.C.,
BIENIAS J.L., WILSON R.S., AGGARWAL N.T.,
SCHERR P.A.: Relation of the tocopherol forms to
incident Alzheimer disease and to cognitive change.
Am J Clin Nutr Feb 2005; 81: 508-514.
26. MILLER E.R. 3RD, PASTOR-BARRIUSO R.,
DALAL D., RIEMERSMA R.A., APPEL L.J.,
GUALLAR E.: Meta-analysis: high-dosage vitamin
E supplementation may increase all-cause mortalità.
Ann Intern Med Jan 2005; 142: 140.
27. KLATTE E.T., SCHARRE D.W., NAGARIJA
N.H., et al.: Combination therapy of donepezil and
vitamin E in Alzheimer’s disease. Alzheimer Disease
and Associated Disorders, 2003; vol 17, n° 2.
28. PETERSEN R.C., THOMAS R.G., GRUNDMAN
M., BENNETT D., DOODY R., FERRIS S., et al.:
Vitamin E and Donepezil for the treatment of Mild
Cognitive Impairment. N Engl J Med April 2005;
352.
29. MÜNCH G., KUHLA B., LÜTH H.J., ARENDT
T, ROBINSON S.R.: Anti-AGEing defences against
Alzheimer’s disease. Biochem Soc Trans 2003; 1397-
1399.
30. WEYER G., BABEY-DOLLE R.M., HADLER D.,
HOFMAN S., HERRMANN W.M.: A controlled
study of two doses of idebenone in the treatment of
Alzheimer’s disease. Neuropsychobiology 1997; 36:
73-82.
31. THAL L.J., CARTA A., CLARKE W.R., FERRIS
Vol. XVIII n. 4 - Luglio/Agosto 2006 255